Outlook Therapeutics (OTLK) Registration filing summary

Company overview and business model

• Focuses on developing and commercializing LYTENAVA™ (bevacizumab gamma), the first ophthalmic formulation of bevacizumab approved in the EU and UK for wet AMD treatment.

• Launched in Germany and the UK in June 2025, with plans for further EU expansion and potential US launch pending FDA approval.

• Targets significant unmet need in anti-VEGF retina markets, with global market estimated at $16 billion.

• Holds multiple US and international patents related to antibody formulations and methods, with expirations extending to 2037.

Financial performance and metrics

• Closed a securities offering on April 23, 2026, raising $4.2 million in net proceeds.

• Audit report notes recurring losses, negative cash flows, and an accumulated deficit, raising substantial doubt about ability to continue as a going concern.

Use of proceeds and capital allocation

• Net proceeds from warrant exercises, if any, will be used primarily for working capital and general corporate purposes.

• No proceeds will be received from the resale of shares by selling stockholders.